前瞻性记忆门诊队列中血液生物标志物的诊断性能与临床适用性
该前瞻性真实世界记忆门诊队列纳入349例疑似认知障碍患者和36例认知未受损对照,评估5种血浆生物标志物的诊断性能。血浆p-tau181和GFAP对区分阿尔茨海默病与非神经退行性病因具有高诊断准确性(AUC分别为0.94和0.92),p-tau181预测淀粉样蛋白状态的灵敏度和特异度均为85%。p-tau181联合NfL识别额颞叶痴呆的灵敏度为82%、特异度为85%。
要点
- 血浆p-tau181预测淀粉样蛋白状态的灵敏度和特异度均为85%。
- p-tau181和GFAP区分AD与非神经退行性病因的AUC分别为0.94和0.92。
- p-tau181联合NfL识别FTD的灵敏度82%、特异度85%。
核心结论
- 血浆p-tau181以高准确度预测淀粉样蛋白状态,在记忆门诊环境中可能使约60%的受试者避免CSF/淀粉样蛋白PET检测。
- NfL有助于从非神经退行性病因中识别FTD,但在所有其他比较中表现劣于p-tau181。
- p-tau181联合NfL改善了FTD和非神经退行性诊断的诊断性能,但14%的假阴性结果提示在记忆门诊之外实施前需要进一步改进。
研究设计与样本
- 前瞻性、真实世界记忆门诊队列研究,2019年7月至2021年6月连续邀请疑似认知障碍患者参与。
- 纳入349例参与者(平均年龄68岁,SD 8.3岁)和36例认知未受损对照(平均年龄61.7岁,SD 8.2岁)。
- 采用单分子阵列技术测定5种血浆生物标志物:p-tau181、GFAP、NfL、t-tau和UCH-L1。
- 以临床诊断(对血浆结果设盲)和淀粉样蛋白状态(CSF/PET)为参照评估诊断性能。
主要发现
- 在具有AD生物标志物的亚队列(n=268)中,血浆p-tau181和GFAP区分AD与非神经退行性病因的AUC分别为0.94和0.92,p-tau181系统性地优于GFAP。
- 血浆p-tau181预测淀粉样蛋白状态的灵敏度和特异度均为85%,约60%的患者获得准确的个体预测。
- 血浆NfL区分FTD综合征与认知未受损对照的AUC为0.90,区分FTD与非神经退行性病因的AUC为0.93,但与AD的区分能力及在所有神经退行性与非神经退行性病因之间的区分能力准确性较低。
- p-tau181联合NfL识别FTD的灵敏度为82%、特异度为85%,对神经退行性诊断的阴性预测值为86%,排除了半数非神经退行性诊断。
- 在无AD生物标志物的亚队列中获得了相似结果;t-tau和UCH-L1未提供附加诊断价值。
关键数值与推荐
- 血浆p-tau181区分AD与非神经退行性病因的AUC为0.94,GFAP为0.92。
- 血浆p-tau181预测淀粉样蛋白状态的灵敏度和特异度均为85%。
- 血浆NfL区分FTD与认知未受损对照的AUC为0.90,区分FTD与非神经退行性病因的AUC为0.93。
- p-tau181联合NfL识别FTD的灵敏度为82%、特异度为85%,对神经退行性诊断的阴性预测值为86%。
临床怎么用
- 作者认为,血浆p-tau181以高准确度预测淀粉样蛋白状态,在记忆门诊环境中可能使约60%的受试者避免CSF/淀粉样蛋白PET检测。
- 作者认为,NfL有助于从非神经退行性病因中识别FTD,但在所有其他比较中表现劣于p-tau181。
- 作者认为,p-tau181联合NfL改善了FTD和非神经退行性诊断的诊断性能。
- 作者指出,14%的假阴性结果提示在记忆门诊之外实施前需要进一步改进。
局限性
- 14%的假阴性结果提示在记忆门诊之外实施前需要进一步改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Blood-based biomarkers have emerged as minimally invasive options for evaluating cognitive impairment. Most studies to date have assessed them in research cohorts, limiting their generalization to everyday clinical practice. We evaluated their diagnostic performance and clinical applicability in a prospective, real-world, memory clinic cohort. METHODS: All patients referred with suspected cognitive impairment between July 2019 and June 2021 were prospectively invited to participate. Five plasma biomarkers (tau phosphorylated at threonine 181 [p-tau181], glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], total tau [t-tau], and ubiquitin C-terminal hydrolase L1 [UCH-L1]) were determined with single-molecule array. Performance was assessed in comparison to clinical diagnosis (blinded to plasma results) and amyloid status (CSF/PET). A group of cognitively unimpaired (CU) controls was also included. RESULTS: Three hundred forty-nine participants (mean age 68, SD 8.3 years) and 36 CU controls (mean age 61.7, SD 8.2 years) were included. In the subcohort with available Alzheimer disease (AD) biomarkers (n = 268), plasma p-tau181 and GFAP had a high diagnostic accuracy to differentiate AD from non-neurodegenerative causes (area under the receiver operating characteristic curve 0.94 and 0.92, respectively), with p-tau181 systematically outperforming GFAP. Plasma p-tau181 levels predicted amyloid status (85% sensitivity and specificity) with accurate individual prediction in approximately 60% of the patients. Plasma NfL differentiated frontotemporal dementia (FTD) syndromes from CU (0.90) and non-neurodegenerative causes (0.93), whereas the discriminative capacity with AD and between all neurodegenerative and non-neurodegenerative causes was less accurate. A combination of p-tau181 and NfL identified FTD with 82% sensitivity and 85% specificity and had a negative predictive value for neurodegenerative diagnosis of 86%, ruling out half of the non-neurodegenerative diagnoses. In the subcohort without AD biomarkers, similar results were obtained. T-tau and UCH-L1 did not offer added diagnostic value. DISCUSSION: Plasma p-tau181 predicted amyloid status with high accuracy and could have potentially avoided CSF/amyloid PET testing in approximately 60% of subjects in a memory clinic setting. NfL was useful for identifying FTD from non-neurodegenerative causes but behaved worse than p-tau181 in all other comparisons. Combining p-tau181 and NfL improved diagnostic performance for FTD and non-neurodegenerative diagnoses. However, the 14% false-negative results suggest that further improvement is needed before implementation outside memory clinics. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that plasma p-tau181 correlates with the presence or absence of AD and a combination of plasma p-tau181 and NfL correlates moderately well with a diagnosis of FTD.
引用
- Sarto J, Ruiz-García R, Guillén N, et al. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Neurology. 2022. PMID: 36450604. doi:10.1212/WNL.0000000000201597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。